Cereno Scientific to present preclinical data for drug candidates CS014 and CS585 at the 65th ASH Annual Meeting & Exposition 2023
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that two abstracts on the preclinical drug candidate CS014 and CS585, respectively, have been accepted and will be presented at the 65th ASH Annual Meeting & Exposition organized by the American Society of Hematology, in San Diego, US, on December 9-12, 2023.The abstract titled “HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding”, was authored by L. Stanger, M. Holinstat, S.